Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023,

Haitong International released a research report on April 10 stating that Sinopharm shares (600511.SH) were given an superior market rating, and the target price was 47.60 yuan. The main reasons for the rating include: 1) revenue growth of 9.23% in 2023, and net profit growth of 9.26%; 2) the direct sales business in Beijing grew steadily, and the market position continued to lead; 3) the national distribution business continued to grow and the quality of operation in the industrial sector improved; 4) the leading position in the distribution of hemp essence drugs was stable, and the profit contribution of joint ventures was steady. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 11 07:34

Individual Investors Own 29% of China National Medicines Corporation Ltd. (SHSE:600511) Shares but Private Companies Control 56% of the Company

Key Insights The considerable ownership by private companies in China National Medicines indicates that they collectively have a greater say in management and business strategy 55% of the company is

Simply Wall StApr 11 06:03

Sinopharm Co., Ltd. (600511): Steady annual revenue growth and gradual improvement in operating quality

In 2023, revenue increased 9.23%, and net profit to mother increased 9.26%. In 2023, the company's revenue was 49.696 billion yuan, up 9.23% year on year; net profit to mother was 2.146 billion yuan, year-on-year

海通證券Apr 7 07:56

Zheshang Securities: An important new business format that is currently breaking the pharmaceutical market, the future of the CSO sector may support the growth of relevant industry targets, etc.

The Zhitong Finance App learned that Zheshang Securities released a research report stating that profitability is related to product IP ownership, product development stage, and CSO's empowerment of products. In the future, the profitability of the CSO business is expected to continue to improve as the product structure gradually matures and the proportion of its own IP products increases. At this stage, based on judging the current macroeconomic environment and the direction of continuous deepening of medical reform, the CSO sector is an important new business format for breaking the current pharmaceutical market. Changes in business trends may support the growth and profitability of the internal standards of the business format to exceed market expectations. Recommended attention: It has proven its own brand marketing capabilities, and has mature sales channels and capabilities

Zhitong FinanceMar 27 11:24

Sinopharm Co., Ltd. (600511: Performance is in line with expectations, maintains a leading edge in the narcotics sector

Core idea: The company publishes its 2023 annual report. In 2023, the company achieved revenue of 49.696 billion yuan (+9.23%, the following are all year-on-year ratios), net profit to mother of 2.46 billion yuan (+9.26%), deductions

廣發證券Mar 27 00:00

Sinopharm Co., Ltd. (600511): The fee control effect is remarkable, and I am optimistic about steady growth throughout '24

Core idea On March 20, the company released its 2023 annual results report, achieving operating revenue of 49.696 billion yuan, a year-on-year increase of 9.23%, and net profit to mother of 2,146 billion yuan, an increase of 9.26% over the previous year.

中信建投證券Mar 25 18:36